Edwards Lifesciences (NYSE: EW) exec exercises options, sells 9,628 shares
Rhea-AI Filing Summary
Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences, exercised employee stock options covering 9,628 shares of common stock at $74.02 per share on July 28, 2026, then sold 9,628 shares at $85.06 per share the same day. Following the exercise, 9,628 derivative option securities are reported as held.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 9,628 shares ($106K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Markowitz Wayne
Role
CVP, JAPAC
Sold
9,628 shs ($819K)
Approx. gross sale proceeds
$819K
Approx. exercise cost
$713K
Approx. pre-tax spread
$106K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Acquire) | 9,628 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,628 | $74.02 | $713K |
| Sale | Common Stock | 9,628 | $85.06 | $819K |
Holdings After Transaction:
Employee Stock Option (Right to Acquire) — 9,628 shares (Direct);
Common Stock — 21,679.8708 shares (Direct)
Key Figures
Options Exercised: 9,628 shares
Exercise Price: $74.02 per share
Shares Sold: 9,628 shares
+4 more
7 metrics
Options Exercised
9,628 shares
Employee stock options exercised into common stock on July 28, 2026
Exercise Price
$74.02 per share
Exercise price of employee stock options converted into common stock
Shares Sold
9,628 shares
Common stock sold on July 28, 2026 after option exercise
Sale Price
$85.06 per share
Price per share for common stock sale on July 28, 2026
Options Remaining
9,628 derivative securities
Total derivative option securities reported as held after the exercise
Option Exercise Date
September 14, 2024
Exercise date for the employee stock option grant
Option Expiration Date
September 13, 2030
Expiration date of the employee stock option grant
Key Terms
Employee Stock Option (Right to Acquire), derivative security, beneficial ownership, Common Stock
4 terms
Employee Stock Option (Right to Acquire) financial
"Security title is listed as "Employee Stock Option (Right to Acquire)""
derivative security financial
"Transaction code M is described as "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial ownership financial
"Remarks note it reflects changes in "beneficial ownership" only"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Common Stock financial
"Underlying security title and transaction security title are "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Wayne Markowitz report for Edwards Lifesciences (EW)?
Wayne Markowitz reported exercising employee stock options for 9,628 shares of Edwards Lifesciences common stock at $74.02 per share, then selling 9,628 shares at $85.06 per share on July 28, 2026.
What options did Wayne Markowitz exercise in his Edwards Lifesciences (EW) filing?
He exercised 9,628 employee stock options with an exercise price of $74.02 per share. These options relate to Edwards Lifesciences common stock and have an expiration date of September 13, 2030, with an exercise date of September 14, 2024.
Were any derivative securities still held by Wayne Markowitz after the Edwards Lifesciences (EW) transactions?
After the reported transactions, 9,628 derivative option securities linked to Edwards Lifesciences common stock are shown as held. This reflects remaining employee stock options under the reported grant following the exercise on July 28, 2026.
Was Wayne Markowitz’s Edwards Lifesciences (EW) trade part of a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating the transactions are not identified as made under a Rule 10b5-1 trading plan. No footnotes specify any separate pre-arranged trading arrangement.